Laser Assisted Celecoxib Treatment of Oral Leukoplakia

激光辅助塞来昔布治疗口腔白斑

• 批准号: 7024999
• 负责人: ZHI WANG
• 金额: $ 19.71万
• 依托单位: BOSTON UNIVERSITY MEDICAL CAMPUS
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-03-01 至 2008-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7024999
• 关键词: cancer prevention; combination therapy; drug screening /evaluation; gastrointestinal disorder chemotherapy; hamsters; laser therapy; nonhuman therapy evaluation; nonsteroidal antiinflammatory agent; oral leukoplakia; oxidoreductase inhibitor; preneoplastic state

DESCRIPTION: Oral leukoplakia is a common clinical finding with a high rate of malignant transformation. Its accumulative features strongly support the rationale for its prevention before invasive lesions can grow. Oral cancer chemoprevention is very promising strategy. Nevertheless, current approaches are very far from being satisfactory because of their significant toxicity. Anti-angiogenesis has been known as one of cornerstones for cancer prevention. Our previous studies have indicated the effectiveness for tumor inhibition of laser selective microvascular targeting (MVT) with a 585 pulsed dye laser (PDL). There was also a significantly synergic effect found between the PDL and some chemopreventive agents. In this proposed study by using check pouch of a hamster model, we will determine 1) if we can further optimize laser parameters for highly-selective MVT treatment for oral mucosa; 2) if Celecoxib, a newly developed less toxic inhibitor of cyclooxygenase (COX)-2, will is safe and effective in treatment of oral leukoplakia; and 3) if there is a synergic effect when combined Celecoxib with PDL, to allow further reduction of potential side-effect with Celecoxib, without sacrificing its treatment efficacy. This is the first study in using a MVT technique for treatment of oral leukoplakia and in combining MVT with Celecoxib for oral cancer chemoprevention. This combined strategy of Celecoxib and PDL, if success in this proposed study, will provide a new and ideal way, called "photo-chemoprevention", for treatment of oral leukoplakia. This new therapy will be more efficacious and less toxic, and is safe and convenient enough to permit an out-patient treatment. The same concept and approach also is available for skin or other pre-malignant lesion located on tissue surface.

描述：口腔白斑是一种常见的临床表现，恶变率高。它的累积特征有力地支持了在侵袭性病变生长之前进行预防的理论基础。口腔癌的化学预防是非常有前景的策略。然而，目前的方法远远不能令人满意，因为它们具有显著的毒性。抗血管生成一直被认为是癌症预防的基石之一。我们以前的研究表明，585脉冲染料激光(PDL)激光选择性微血管靶向(MVT)对肿瘤的抑制作用是有效的。PDL与一些化学预防药物之间也有显著的协同作用。在这项拟通过金黄地鼠模型的支票袋进行的研究中，我们将确定1)是否可以进一步优化用于高选择性口腔黏膜MVT治疗的激光参数；2)新开发的毒性较低的环氧合酶(COX)-2抑制剂塞来昔布是否安全有效地治疗口腔白斑；3)塞来昔布与PDL联合使用是否有协同效应，从而在不牺牲其治疗效果的情况下进一步减少塞来昔布的潜在副作用。这是首次使用MVT技术治疗口腔白斑，并将MVT与塞来昔布联合用于口腔癌化学预防的第一项研究。塞来昔布和PDL的这种联合策略，如果在这项拟议的研究中成功，将为口腔白斑的治疗提供一种新的、理想的方法，称为“光化学预防”。这种新疗法将更有效，毒性更低，而且足够安全和方便，可以进行门诊治疗。同样的概念和方法也适用于皮肤或其他位于组织表面的癌前病变。